# Gestion De Capital Riesgo Del Pais Vasco

> Gestion De Capital Riesgo Del Pais Vasco is a VC fund backing Biotechnology and Health Care. See 23 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Bilbao, Spain
- Total investments: 23
- Last investment: May 2026
- Lead investor: 35%
- Last fund: Jan 2014
- Last updated: Aug 2026
- Website: http://www.gestioncapitalriesgo.com

Gestion De Capital Riesgo Del Pais Vasco is a VC fund in Bilbao focused on Biotechnology and Health Care. Gestión de Capital Riesgo del País Vasco SGECR, S.A. is a venture capital entity management company founded in 1985 by the Basque Government as part of the Sociedad para la Promoción y Reconversión Industrial (SPRI), with the aim of promoting and developing venture capital activity in the Basque Country.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $213k–$2.3M |
| Series A | $329k–$13M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 22% |
| Health Care | 4 | 17% |
| Medical | 3 | 13% |
| Software | 3 | 13% |
| E-Commerce | 2 | 9% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 9 | 39% |
| Seed | 6 | 26% |
| Series A | 2 | 9% |
| Pre-Seed | 1 | 4% |
| Series B | 1 | 4% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 18 | 78% |
| Ecuador | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Orbik Cybersecurity | Orbik Cybersecurity provides testing and compliance services for industrial equipment and embedded electronics. | $2.3M | Seed | May 19, 2026 |  |
| InspectRail | InspectRail was established to offer high-quality information on the state of railway infrastructure, thereby enhancing its operation, management, and maintenance. | $357.9K | Pre-Seed | Mar 01, 2024 |  |
| Inmedical Therapeutics | Inmedical Therapeutics is centered on the creation of the Covergel product, which is intended to avoid difficulties in therapeutic endoscopies | $870.8K | Seed | Jan 17, 2024 |  |
| Irisbond | Irisbond creates a new way for humans to communicate through precision eye-tracking technology. Irisbond’s advanced software algorithms interpret your eye gaze in order to provide natural, intuitive and hands-free access to information and control over a screen. Developed for use in mobile devices, automotive, smart homes, robotics, scientific,healthcare and manufacturing, eye tracking technology lets you learn, play, work and communicate with your eyes. A pioneer in the assistive technology market, Irisbond’s eye tracking solutions are based on years of R&D in cooperation with Vicomtech, a leader in the field of artificial vision. For more information about the power of the eyes, go to www.irisbond.com/en |  |  | Sep 28, 2023 |  |
| Cocoon Bioscience | Cocoon Bioscience helps catalyze the expansion of bottlenecked industries like cultivated meat by manufacturing performance and growth factors and specialized enzymes for individual protein, nutrition, and healthcare applications. | $16.1M | Venture - Series Unknown | Mar 14, 2023 |  |
| H2SITE | Systems and Membranes for high efficiency and purity Hydrogen production i.e. for Separation or Ammonia cracking | $13.2M | Series A | Jun 28, 2022 |  |
| Fesia Technology | Fesia Technology is working in a new generation of medical devices based on functional electrical stimulation to use in rehabilitation therapy for people who have suffered injuries and neuromuscular diseases. Based on the technology of functional electrical stimulation, Fesia has developed an innovative system of functional stimulation using anelectrode with matrix arrangement. Fesia Walk, for foot drop patients, has been already presented on the market and it is the first device of this new generetaion based on Fesia Technology. | $847K | Equity Crowdfunding | Feb 19, 2019 |  |
| Irisbond | Irisbond creates a new way for humans to communicate through precision eye-tracking technology. Irisbond’s advanced software algorithms interpret your eye gaze in order to provide natural, intuitive and hands-free access to information and control over a screen. Developed for use in mobile devices, automotive, smart homes, robotics, scientific,healthcare and manufacturing, eye tracking technology lets you learn, play, work and communicate with your eyes. A pioneer in the assistive technology market, Irisbond’s eye tracking solutions are based on years of R&D in cooperation with Vicomtech, a leader in the field of artificial vision. For more information about the power of the eyes, go to www.irisbond.com/en |  | Series B | Jan 08, 2018 |  |
| Histocell SL | Histocell SL is a biopharmaceutical company that develops cell therapy products and novel medical devices for regenerative medicine.Histocell works to improve people’s quality of life by creating new Cell Therapy medicaments. Histocell facilities (567 m2) include a 65 m2 GMP-certified manufacturing facility for cell therapy medicinal products,and several laboratories for quality control and R&D activities. Histocell team meets the maximum quality standards through GMP and ISO 9001/2000 certifications. | $4.4M |  | Sep 30, 2016 |  |
| Hapiick | Hapiick is the emergence of e-commerce as a purchase formula causes a growing demand for logistics associated with the delivery of packages to the consumer. Home deliveries are difficult for the logistics operator with a significant percentage (1 in 4) of unsuccessful attempts at delivery, which represents an inconvenience and an important handicapwith current schedules and pace of life. Happiick is proposed as an innovative service to alleviate this situation that affects a significant number of users who buy online. |  | Seed | Feb 04, 2016 |  |

10 of 23 investments shown.

## Co-investors
- [Seed Capital Bizkaia](https://shizune.co/investors/profile/seed-capital-de-bizkaia) — VC Fund, 3 deals together
- [Viscofan](https://shizune.co/investors/profile/viscofan-group) — VC Fund, 2 deals together
- [Algenex](https://shizune.co/investors/profile/algenex) — VC Fund, 1 deal together
- [BeAble Capital](https://shizune.co/investors/profile/b-able) — VC Fund, 1 deal together
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund, 1 deal together
- [Criteria Venture Tech](https://shizune.co/investors/profile/caixa-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in Spain](https://shizune.co/investors/health-care-investors-spain)
- [Health Care VC Funds in Spain](https://shizune.co/investors/health-care-vc-funds-spain)
- [Biotechnology Investors in Spain](https://shizune.co/investors/biotechnology-investors-spain)
- [Biotechnology VC Funds in Spain](https://shizune.co/investors/biotechnology-vc-funds-spain)
- [Biotech Investors in Spain](https://shizune.co/investors/biotech-investors-spain)
- [Biotech VC Funds in Spain](https://shizune.co/investors/biotech-vc-funds-spain)

## FAQ

### What does Gestion De Capital Riesgo Del Pais Vasco invest in?

Gestion De Capital Riesgo Del Pais Vasco invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Seed stage. Most of the 23 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Gestion De Capital Riesgo Del Pais Vasco's check size?

Gestion De Capital Riesgo Del Pais Vasco typically joins rounds of $213k–$2.3M at Seed and $329k–$13M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gestion De Capital Riesgo Del Pais Vasco participates in.

### When did Gestion De Capital Riesgo Del Pais Vasco last invest?

The most recent investment recorded for Gestion De Capital Riesgo Del Pais Vasco closed in May 2026. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co